LXRX vs AQST โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LXRX Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lexicon Pharmaceuticals, Inc. (LXRX) driven by superior Momentum & Technical, Options & Structure while AQST counters with relative strength in Growth & Margin. Fundamentally, LXRX trades at N/M Forward P/E with -147.4% operating margin (-20.7% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, LXRX sits in BREAKDOWN (59th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LXRX Revenue | AQST Revenue | LXRX Op. Margin | AQST Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $70M | -388.5% | -72.6% | AQST |
| FY2019 | $30M | $50M | 437.5% | -100.1% | LXRX |
| FY2020 | $20M | $50M | -204.2% | -93.6% | AQST |
| FY2021 | N/A | $50M | N/A | -68.2% | AQST |
| FY2022 | N/A | $50M | N/A | -88.2% | AQST |
| FY2023 | $0M | $50M | -15473.0% | -29.9% | AQST |
| FY2024 | $10M | $60M | -3284.7% | -53.5% | AQST |
| FY2025 | $50M | $40M | -98.2% | -159.5% | LXRX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LXRX | AQST | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $743.5M | $465.7M | Larger Scale | LXRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -20.7% | -41.0% | Higher Growth | LXRX |
| Operating Margin (TTM) Profitability | -147.4% | -114.1% | Higher Margin | AQST |
| Net Profit Margin Profitability | -161.8% | -162.3% | Higher Margin | LXRX |
| Return on Equity (ROE) Capital Efficiency | -43.9% | 0.0% | Higher ROE | AQST |
| 52-Week Range Position Momentum | 27% ($1โ$3) | 14% ($3โ$7) | Stronger Trend | LXRX |
| Beta / 30D Volatility Risk Regime | 0.85ฮฒ ยท 69% Vol | 0.89ฮฒ ยท 56% Vol | Lower Realized Risk | AQST |
| Unified Institutional Score Composite Signal | 48.7 / 100 (HOLD) | 62.9 / 100 (BUY) | Higher Composite | AQST |